Gujarat Themis Biosyn QIP Plan: ₹1,000 Cr Fundraise in 2026

Fundraise proposal: QIP plus preferential issue

Gujarat Themis Biosyn has outlined a plan to raise up to ₹1,000 crore through a Qualified Institutions Placement (QIP), in compliance with SEBI’s Issue of Capital and Disclosure Requirements (ICDR) Regulations. Alongside the QIP route, the company has also indicated that additional funds may be raised via a preferential issue of equity shares to non-promoters, subject to approvals. The company’s disclosures indicate that the capital raise could involve equity shares and or other securities, including convertible instruments such as warrants. The final structure, choice of instrument, and investor details are not yet fixed. Those specifics are to be determined by the company’s Fund-Raising Committee and disclosed later.

Board meeting schedule and agenda

The company informed exchanges that its board would convene on June 6, 2026, to consider and evaluate proposals for raising funds. The stated options included a QIP, preferential allotment, or other permissible methods or combinations under SEBI regulations. The same set of disclosures noted that the fundraise is subject to obtaining necessary regulatory and statutory approvals. A separate timeline item also referenced “Fund Raising Approval” dated June 06, 2026, and an earlier item stating “Gujarat Themis Biosyn to consider fund raising proposals at board meeting on June 6, 2026” dated Jun 03, 2026.

What is known about the issue structure so far

From the information provided, the fundraise framework remains broad, with flexibility on instruments and sequencing. The QIP is described as being undertaken under SEBI ICDR Regulations, and it may include equity shares and or convertible securities. The preferential issue is described as an issuance of equity shares to non-promoters, and it is explicitly stated to be subject to approvals. The company has also indicated that names of investors and other final details will be decided later by the relevant committee and subsequently disclosed.

Shareholder approvals for higher financial flexibility

Separately, Gujarat Themis Biosyn shareholders have approved special resolutions to increase borrowing limits and expand inter-corporate investment capabilities. Both resolutions reportedly passed with over 98% votes in favour. The company described these approvals as enabling greater financial flexibility. The disclosures do not specify the revised borrowing limit amount or the revised investment thresholds, but they clearly indicate the governance clearances were obtained with a strong voting margin.

Dividend recommendation and audited profit reference

In another regulatory update referenced in the provided text, the company reported FY26 audited profit of ₹46.68 crore. The board also recommended a final dividend of Re. 0.67 per share. The dividend was described as 67% of the face value of Re. 1 each. The company also disclosed a total dividend payout aggregating to ₹7,30,06,728, subject to shareholder approval at the ensuing Annual General Meeting.

A separate disclosure also referenced that the dividend would be subject to shareholder approval at an Annual General Meeting to be held on 12 September, 2025. That section stated the dividend recommendation of Re. 0.67 per equity share was on 10,89,65,265 equity shares and repeated the aggregate dividend amount of ₹7,30,06,728 for the financial year ended 31 March, 2025.

Cost auditor appointment and committees for the issue

The board approved the appointment of M/s. Raja Dutta & Co., Cost Accountants, as the cost auditor for the financial year 2026-27. It also approved a proposal for a preferential issue of equity shares to non-promoters. A Preferential Issue Committee has been constituted to finalise the terms and conditions of the proposed issue, again subject to necessary regulatory and shareholder approvals. In parallel, the QIP-related disclosures note that the Fund-Raising Committee will decide final issue details, including securities and investor names.

Business profile and sector context

Gujarat Themis Biosyn, incorporated in 1981, operates in the pharmaceuticals sector. The company manufactures and markets bulk drugs and intermediates, with specialisation in anti-tuberculosis and antibiotic products. It focuses on fermentation-based APIs and caters to domestic and international pharmaceutical markets. The company’s key products or revenue segments listed for the year ending 31-Mar-2025 include Pharmaceuticals, Raw Materials, and Scrap.

Stock price references reported in the disclosures

The provided text includes multiple price points for Gujarat Themis Biosyn shares. One line states the share price is ₹413.2 as of 6 June, 2026. Another line states the stock moved down by -4.74% from its previous close of ₹424.30 and last traded at ₹404.20. The same collection of data also contains a line stating “The current price of Gujarat Themis Biosyn Ltd is ₹253.10,” without a date attached in the provided content. These figures reflect the reported snippets as presented and may relate to different timestamps or data pulls.

Key facts at a glance

Market impact: what changes materially with a QIP and approvals

A QIP and a preferential issue are capital-raising routes that can change the company’s equity base depending on final sizing and structure, but the disclosures in the provided text stop short of specifying issue price, dilution, or the timeline for tranche execution. What is clearly established is the board and shareholder emphasis on financial flexibility. The approval of higher borrowing limits and expanded inter-corporate investment capability, each supported by over 98% votes, indicates the company has aligned shareholder backing for a wider financing toolkit. The dividend recommendation and the cost auditor appointment signal that the company is also progressing on routine governance items while evaluating a larger capital raise.

Analysis: why the committee-led process matters

The company’s disclosures place meaningful decision-making with designated committees. For the QIP, the Fund-Raising Committee is expected to decide the final details and later disclose them. For the preferential issue, a Preferential Issue Committee is tasked with finalising terms and conditions. This structure suggests the company is keeping flexibility on instrument choice and timing, while staying within SEBI ICDR and LODR disclosure frameworks referenced in the text. Investors tracking the situation will likely focus on subsequent disclosures that spell out the final instrument mix, the allotment size, and the identified investors.

Related corporate actions and historical references

The provided text also referenced a bonus issue approved earlier. On 14 May, 2024, the board approved a bonus issue in the ratio of 1:2, which was approved by shareholders at the AGM on 23 July, 2024. The record date was set as 9 August, 2024, and allotment was completed on 14 August, 2024. Following the allotment, the paid-up equity share capital increased from ₹7,26,43,510 to ₹10,89,65,265.

Separately, CareEdge Ratings removed the “Rating Watch with Developing Implications (RWD)” on bank facilities of Gujarat Themis Biosyn, reaffirmed ratings, and assigned a “Stable” outlook following the company’s June 13, 2025 announcement about withdrawal of an amalgamation scheme with Themis Medicare.

Conclusion

Gujarat Themis Biosyn has signalled a potential capital raise of up to ₹1,000 crore via QIP, with scope for an additional preferential issue to non-promoters, while also securing shareholder approvals to increase borrowing and broaden inter-corporate investment flexibility. The next set of disclosures from the Fund-Raising Committee and Preferential Issue Committee will be key to understanding the final instrument structure, investor participation, and approval milestones.